Furthermore, the authors summarized the incidence of specific adverse reaction types, which provided ideas and data for the subsequent exploration of the relationship between neurological adverse reactions and PD-1/PD-L1 immunotherapy, further between the nervous system and cancer treatment. The gene discussed is PDCD1; the disease is cancer.